



Press Release

Date: May 20, 2025

Dr. Ashleys Limited Unaffected by Global Tariff Conflicts

Dr. Kanans Visvanants, FRSC (Dr. Kanans), Chairman, announced: “Dr Ashleys Limited is Unaffected by Global Tariff Conflicts. As a global company, Dr. Ashleys markets its products to over 80 countries outside of the United States via a network of over 100 distributors and 200 pharmaceutical companies in Europe, Africa, the Middle East, India, and Southeast Asia. Therefore, we unaffected by global tariff disputes, operating independently of domestic policies and politics. Our business model transcends policy and politics.”

Dr. Ashleys Limited is a historically profitable pharmaceutical company dedicated to the development and manufacturing of specialized and complex active pharmaceutical ingredients (APIs) and orphan drugs for rare diseases. The company's expertise spans across various critical health areas, including malaria, cancer, gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases.

Under the visionary leadership of Dr. Kanans Visvanants FRSC (Dr. Kanans), a second-generation pharmaceutical and chemical engineer, the company revolutionized the industry by significantly reducing the cost of manufacturing generic and patented drugs. With 15 manufacturing patents, the company provides over 300 million annual medical doses to the world's disease epicenters, addressing both non-communicable diseases (NCDs) and infectious diseases.

####

For Dr Ashleys Limited Contact:

William Keegan

President, CEO

Capital Formation Marketing, LLC

Phone: (516) 435-8365

wkeegan@cfmct.com